IMV (Halifax)

IMV, a clinical-stage biopharmaceutical company recently announced that it is advancing the clinical development of a DPX-based vaccine candidate against COVID-19. Vaccines against infectious disease have been a core part of IMV’s heritage across its DPX platform technology.

Learn More